• Molecular NameMitoxantrone
  • SynonymDHAD; DHAQ; DHAQ HCl; Dihydroxyanthraquinone; Mitoxanthrone; Mitoxantron; Mitoxantrona [INN-Spanish]; mitoxantrone; Mitoxantrone 2HCl; Mitoxantrone dihydrochloride; Mitoxantrone HCl; Mitoxantrone hydrochloride; Mitoxantronum [INN-Latin]; Mitozantrone; Mitozantrone hydrochloride
  • Weight444.488
  • Drugbank_IDDB01204
  • ACS_NO65271-80-9
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.55
  • pka5.99 and 8.13
  • LogD (pH=7, predicted)-0.23
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.78
  • LogSw (predicted, AB/LogsW2.0)2.07
  • Sw (mg/ml) (predicted, ACD/Labs)0.34
  • No.of HBond Donors8
  • No.of HBond Acceptors10
  • No.of Rotatable Bonds12
  • TPSA163.18
  • StatusFDA approved
  • AdministrationExclusively intravenous
  • PharmacologyAn Anthracenedione (not an anthracycline) antineoplastic agent.
  • Absorption_valueN/A
  • Absorption (description)Poorly absorbed following oral administration
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding78.0
  • Volume of distribution (VD)90 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life5~18 days. Initial phase 3 to 10 min, intermediate phase 0.3 to 3.1 h, terminal phase 23 to 215 h (mean 75 h). Terminal phase also reported as 37.4 h.
  • ExcretionN/A
  • Urinary Excretion2
  • Clerance13 ml/min/kg
  • ToxicitySevere leukopenia with infection.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A